In a recent turn of events, pharmaceutical giant Cipla witnessed a sharp decline in its share price, dropping over 7% in Thursday’s trade. This sudden downturn followed the issuance of a warning letter by the US Food and Drug Administration (US FDA) to Cipla’s Pithampur unit on November 18. The setback erased gains from the previous two weeks, making Cipla the top laggard in the Nifty 50.
The Regulatory Challenge
The trigger for Cipla’s share price decline is linked to a warning from the US FDA regarding a routine current good manufacturing practices (cGMP) inspection at its Pithampur manufacturing facility. The inspection occurred from February 6–17, 2023, and the warning letter, dated November 17, cited contraventions in methods or controls that do not conform to prescribed cGMP regulations.
Cipla’s Response
In response to the warning letter, Cipla expressed its commitment to quality and compliance in its exchange filing on November 18. The company assured that it would respond within the allotted time frames and collaborate closely with the US FDA to address the identified issues comprehensively and promptly.
Key Financial Metrics
As of the latest data, Cipla’s stock is priced at ₹1170.95, reflecting a per cent change of -7.92 and a net change of -100.7. The 52-week low and high prices stand at ₹852.00 and ₹1283.55, respectively, illustrating the volatility in the stock’s performance.
The Technical View
Technical analysts attribute the decline in Cipla’s share price to its failure to sustain above the August swing high of around ₹1,280. Despite a recent uptrend, today’s weakness has prompted concerns. Rajesh Bhosale, Equity Technical and Derivative Analyst at Angel One, suggests that the following support for Cipla’s shares lies in the range of 1160 – 1150. He advises caution in initiating fresh long positions until signs of a base or reversal emerge.
Ruchit Jain, Lead Research Analyst at 5paisa, highlights the negative news flow as the cause of Cipla’s correction. He points out significant resistance around ₹1,280, indicating a potential underperformance of the stock in the near term.
Market Insights
Looking at the futures market, the open interest for Cipla’s November futures is 11,340,550 contracts, underscoring the total number of outstanding contracts. This data provides insights into market sentiment and indicates investor interest in Cipla’s future performance.
Summary
Cipla’s recent share price slump serves as a cautionary tale for investors, emphasizing the impact of regulatory challenges on stock performance. As the company navigates the corrective measures outlined in the warning letter, market participants will watch for signs of recovery and regulatory compliance in the coming weeks.
Disclaimer: We do not endorse or encourage you to take trades or investment decisions based upon our posts/research, all of your trading and investment activities are your own and should be taken through consultation with reputed financial advisors. The analysis posted on this website has been created by involving multiple mediums which are present over the Internet.